New biobank aims to unlock prostate cancer secrets in High-Risk genes

NCT ID NCT06659614

Recruiting now Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is building a collection of prostate tissue samples from people who carry certain gene mutations (like BRCA1/2) that raise their risk for aggressive prostate cancer. Researchers will compare these samples with those from people without the mutations to learn how the cancer develops and responds to treatment. The goal is to better understand and eventually improve care for those at highest genetic risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited disease susceptibility prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETIC PREDISPOSITION PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-••••

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Phone: •••-•••-••••

Contact Phone: •••-•••-••••